Literature DB >> 23175767

Innovative trial designs to improving tuberculosis drug development.

Lori E Dodd, Michael A Proschan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23175767      PMCID： PMC3537451          DOI： 10.1093/infdis/jis704

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  1 in total

1.  Innovative trial designs are practical solutions for improving the treatment of tuberculosis.

Authors:  Patrick P J Phillips; Stephen H Gillespie; Martin Boeree; Norbert Heinrich; Rob Aarnoutse; Tim McHugh; Michel Pletschette; Christian Lienhardt; Richard Hafner; Charles Mgone; Alimuddin Zumla; Andrew J Nunn; Michael Hoelscher
Journal:  J Infect Dis       Date:  2012-03-22       Impact factor: 5.226
  1 in total
  1 in total

1.  Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.

Authors:  Payam Nahid; Erin Bliven-Sizemore; Leah G Jarlsberg; Mary A De Groote; John L Johnson; Grace Muzanyi; Melissa Engle; Marc Weiner; Nebojsa Janjic; David G Sterling; Urs A Ochsner
Journal:  Tuberculosis (Edinb)       Date:  2014-02-07       Impact factor: 3.131
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.